An umbilical vein model was designed in which washed vein segments are filled with a reaction mixture containing factor Vlla, Ca", and a substrate, either 3H-factor IX or 3H-factor X. The vein wall provides the tissue factor (TF) for factor Vlla/TF complexes that activate the substrates as measured by activation peptide release. The model was developed t o study TF induced on venous endothelium in situ. However, unlike previous studies with TF expressed on cultured umbilical vein endothelial cells, factors IX and X were activated without first having t o expose the vein wall t o a perturbing stimulus. Histologic studies revealed that washing the vein and mixing the reaction mixture before subsampling had disrupted the endothelium. Immunostaining with anti-TF antibodies revealed no staining of endothelium but intense staining in extensions of Wharton's jelly penetrating fenestrations of the muscularis media of the vein. Thus, the model provided data on factor Vlla/TF E RECENTLY reported' that factor VIIa/tissue W factor (TF) complexes formed with TF expressed on the plasma membrane of perturbed, cultured human umbilical vein endothelial cells (HUVEC) did not differ in functional properties from factor VIIa/TF complexes made with purified TF reconstituted into mixed phospholipid vesicles. Knowing that the expression of TF on perturbed HUVEC can vary with culture conditions,2 we next designed an umbilical vein model for intended use in a study of the functional properties of factor VIIa/TF complexes formed on perturbed venous endothelium in situ. Experiments with this model yielded the initially surprising observation that the umbilical vein possessed activity supporting factor VIIacatalyzed activation of factors IX and X before exposing the vein lumen to a known perturbing stimulus. Moreover, factors IX and X were activated at equivalent rates. We report our data, along with evidence that our results reflect the catalytic activity of factor VIIa/TF complexes formed not on endothelium but within fenestrations of the underly- formed, not on endothelium, but within the mucoid connective tissue of Wharton's jelly. It is known that factor Vlla/TF formed with TF in suspension or with TF expressed on the surface of cultured cells activates factor X more rapidly than factor IX. In contrast, in the umbilical vein model, when each substrate was present in an 88 nmol/L concentration, factors IX and X were activated at equivalent rates (mean activation rate for factor IX, 18.8 f 3.6 nmol/L/h; for factor X, 17.8 ? 2.9 nmol/L/h; n = 9 paired vein segments). These data strengthen the evidence that factor Vlla/TF activation of factor IX t'epresents a key initial reaction of coagulation in tissues. These results also show that data obtained with factor Vlla/TF complexes formed on the surface of cultured cells need not hold for factor Vlla/TF complexes formed in extracellular matrix. ing umbilical vein wall containing extensions of the mucoid connective tissue (Wharton's jelly) of the umbilical cord.
W factor (TF) complexes formed with TF expressed on the plasma membrane of perturbed, cultured human umbilical vein endothelial cells (HUVEC) did not differ in functional properties from factor VIIa/TF complexes made with purified TF reconstituted into mixed phospholipid vesicles. Knowing that the expression of TF on perturbed HUVEC can vary with culture conditions,2 we next designed an umbilical vein model for intended use in a study of the functional properties of factor VIIa/TF complexes formed on perturbed venous endothelium in situ. Experiments with this model yielded the initially surprising observation that the umbilical vein possessed activity supporting factor VIIacatalyzed activation of factors IX and X before exposing the vein lumen to a known perturbing stimulus. Moreover, factors IX and X were activated at equivalent rates. We report our data, along with evidence that our results reflect the catalytic activity of factor VIIa/TF complexes formed not on endothelium but within fenestrations of the underly-formed, not on endothelium, but within the mucoid connective tissue of Wharton's jelly. It is known that factor Vlla/TF formed with TF in suspension or with TF expressed on the surface of cultured cells activates factor X more rapidly than factor IX. In contrast, in the umbilical vein model, when each substrate was present in an 88 nmol/L concentration, factors IX and X were activated at equivalent rates (mean activation rate for factor IX, 18.8 f 3.6 nmol/L/h; for factor X, 17.8 ? 2.9 nmol/L/h; n = 9 paired vein segments). These data strengthen the evidence that factor Vlla/TF activation of factor IX t'epresents a key initial reaction of coagulation in tissues. These results also show that data obtained with factor Vlla/TF complexes formed on the surface of cultured cells need not hold for factor Vlla/TF complexes formed in extracellular matrix. ing umbilical vein wall containing extensions of the mucoid connective tissue (Wharton's jelly) of the umbilical cord.
MATERIALS AND METHODS
Factors VII, IX, and X were purified from human plasma as described previ~usly.'~~ Factor VIIa was prepared by incubating purified factor VI1 with factor Xa in a ratio of 50:l (wt/wt) in the presence of mixed rabbit brain phospholipid (cephalin) and calcium ions. EDTA was added to stop the reaction, and the factor VIIa was stored at -8OOC in small aliquots. Details are provided elsewhere.' Tritiated sialyl factors IX and X were prepared by the general technique of Van Lenten and Ashwell' with slight modifications described earlier! Specific radioactivities were as follows: for 'Hfactor IX, 3.2 x 10' cpm/mg; 'H-factor X, 2.0 x 10' cpm/mg.
Purified human brain T F apoprotein' was reconstituted into mixed phospholipid vesicles as described earlier?
Antibodies. Specific polyclonal anti-TF antiserum' and antifactor VI1 antiserum' were raised in goats. The IgG fraction was separated by precipitation at 45% ammonium sulfate saturation, followed by DEAE-Affi-Gel blue chromatography (Bio-Rad Laboratories, Richmond, CA). A concentration of 4.0 pg/mL of the anti-TF IgG neutralized more than 95% of the activity of 0.05 pg/mL of reconstituted T F apoprotein. One part of a 1,600-fold dilution of the anti-factor VI1 antiserum neutralized 50% of the factor VI1 activity of one part of normal plasma.
Buffer A consisted of 10 mmol/L HEPES, 0.14 mol/L NaCI, 0.004 mol/L KCI, 0.01 1 mol/L glucose, pH 7.45. Buffer B consisted of buffer A plus 1 mg/mL bovine serum albumin (ICN Immunobiologicals, Lisle, IL) and 5 mmol/L CaCL,. Phosphate buffered saline (PBS) was 0.137 mol/L NaCI, 0.0026 mol/L KCI, 0.010 mol/L Na,HPO,, 0.0014 mol/L KH,PO,, pH 7.4. RPMI 1640 was from Whittaker Bioprcducts (Walkersville, MD), and heparin was Liquaemin Sodium (Organon, West Orange, NJ). Purified human thrombin was a gift from Dr J.W. Fenton, State Department of Health, Albany, NY.
Measurement of the activation of factors IX and X within umbilical vein segments. Umbilical cords were from uncomplicated full-term vaginal deliveries or from deliveries by cesarean section done at UCSD Medical Center. After most of the blood from the cord had been expressed by gentle squeezing, the cord was clamped and cut. The placenta and cord were stored in a sterile container at 4OC. Cords were obtained within 2 hours after delivery for most experiments and within 7 hours for all others except a single cord obtained after 15 hours. Cords were processed under sterile Bufers and other reagents.
conditions in a hood. Areas containing clamp marks were cut away and the remainder of the cord was cut into two to four segments of 10 cm each. A siliconized glass tube of 2 mm diameter and 2 cm length was inserted into the lumen of the umbilical vein at each end of a cord segment and secured with a nylon tie (Johnson & Johnson, Anaheim, CA). The other end of the glass tube was inserted into a 1.5 cm length of plastic tubing (Tygon; Fisher Scientific, Pittsburgh, PA). A syringe was attached to one end of the plastic tubing, and 30 mL of PBS were flushed through the cord segment to expel residual blood. The syringe was refilled with PBS and the process was repeated from the other end of the cord segment. After a third 30 mL wash, the effluent was clear of visible blood. As shown in Fig 1, the flexible tubing at one end of the cord segment was sealed with a hemostat, and the vein was filled by syringe from the other end with 3.5 mL of buffer B, usually containing 10 nmol/L factor VIIa and 88 nmol/L of either 'H-factor IX or 'H-factor X. (Factor VIIa was used at a 10 nmol/L concentration because that is the plasma concentration of factor VI1 and because, in earlier experiments,' a concentration exceeding 4 nmol/L was found to saturate fully TF expressed on perturbed monolayers of cultured endothelial cells.) Then the plastic tubing at this end of the cord segment was sealed with a hemostat and the segment was placed in an incubator at 37OC in a humidified CO, (5%) atmosphere. At intervals over the next 2 hours, the reaction mixture within the vein was mixed by back and forth suction with plastic syringes inserted in the flexible tubing of each end of the cord segment, after which an approximately 70 p L sample was removed for measurement of activation peptide release.' The initial linear portion of the progress curves of activation were used to calculate activation rates. One hundred percent activation of factor IX or factor X, as determined by radioactivity profiles on reduced and nonreduced SDS gels, yielded approximately 35% trichloroacetic acid soluble counts. (Reaction mixtures differing from the above in specific experiments are described in Results.)
An indirect immunoperoxidase technique was used to immunostain T F antigen in frozen sections of umbilical cords. A specific, polyclonal, rabbit anti-human T F IgG was used as the primary antibody and a peroxidaseconjugated goat anti-rabbit IgG was used as the secondary antibody. Details of the immunostaining techniques are described elsewhere."
Immunostaining for TF antigens. 
RESULTS
The ability of untreated umbilical vein segments to support factor VIIa-catalyzed activation of factors IX and X . In our previous study,' unperturbed HUVEC monolayers were unable to support factor VIIa-catalyzed activation of factor IX or factor X. Monolayers required incubation with either thrombin or phorbol 12-myristate 13-acetate (PMA) to develop the TF activity needed to support activation. In contrast, when umbilical vein segments were filled with a reaction mixture containing 'H-factor IX or 'H-factor X, factor VIIa, and calcium ions, the substrates were activated without our first having to incubate the vein lumen with either an exogenous source of thrombin or with PMA.
Initially, we thought that thrombin from blood clotting intraluminally before the cord was processed could have triggered the expression of TF activity on the vein endothelium. Therefore, on two occasions, a cord from a cesarean section done before the onset of labor was processed by a technique minimizing the possibility of generation of thrombin within the vein lumen. The umbilical vein was cannulated in the operating suite immediately after cesarean delivery and flushed three times with 30 mL of 25 mmol/L EDTA in either distilled water (one cord) or PBS (second cord). The vein was then washed once with PBS to prevent further possible effects of EDTA upon the umbilical endothelium. The cords were further processed (see Methods), and the vein segments were filled with their reaction mixtures within 15 minutes of the time of delivery. These vein segments possessed procoagulant activity similar to the activity found in the routinely processed cords (Fig 2, data points identified by arrows). Moreover, the ability of umbilical vein segments to support activation of factors IX and X appeared to be independent of the number of hours elapsing between delivery and processing of the cord (Fig 2) . An additional experiment was carried out on two occasions to test whether incubation with exogenous thrombin increased the procoagulant activity of an umbilical vein segment. The lumen of a control segment of a vein was filled with RPMI 1640 containing 0.5% bovine serum albumin (BSA), and the lumen of a second segment of the same vein was filled with the same solution containing 2.5 U/mL thrombin (the concentration used to induce TF activity on cultured HUVEC in earlier experiments.' After 6 hours at 37OC, the veins were washed, and their ability to support factor VIIa-catalyzed activation of factor X was measured. The rate of factor VIIa-catalyzed activation of factor X in the paired segments did not differ; for example, in one experiment the rate of factor X activation within the experimental vein segment was 15.5 nmol/L/h and in the control vein segment, 17.1 nmol/L/h.
Equivalent factor VIIa-catalyzed activation of factors IX
and X in reaction mixtures containing equivalent substrate concentrations. In experiments with nine cords, factor VIIa-catalyzed activation of factor IX was measured in one vein segment and factor VIIa-catalyzed activation of factor X was measured in a second segment from the same cord. The substrate concentration in each segment was 88 nmol/L. Without exception, factor IX and factor X were activated at equivalent rates (Fig 3) . Mean activation rates were as follows: for factor IX, 18.8 3.6 nmol/L/h; for factor X, 17.8 2.9 nmol/L/h. These data differ strikingly from our earlier data, obtained with factor VIIa/TF complexes made either with purified, reconstituted T F or with TF induced on monolayers of cultured HUVEC, in which factor X was always the preferred substrate.' The progress curves of activation in Fig 4A and B show the difference. In a supplemental study done on two occasions, substrate concentrations were chosen to correspond to plasma concentrations of factor X and factor IX (140 nmol/L or 175 nmol/L in the segments containing factor X and 70 nmol/L or 88 nmol/L in the segments containing factor IX). When TIME (min) Fig 4. Progress curves of factor Vlla/TF activation of 'H-factor X (0) and 'H-factor IX (a) by factor Vlla/TF complexes formed with 10 pmol/L reconstituted, purified TF (A) and with factor Vlla/TF complexes formed in paired umbilical vein segments from the same umbilical cord (6). All reaction mixtures contained factor Vila, 10 nmol/L; CaCI,, 6 mmol/L: and either 'H-factor X or 'H-factor IX, 88 nmol/L. Reactions were carried out at room temperature with the purified TF and at 37°C in humidified 5% CO, atmosphere with the umbilical vein pegments. Serial samples were removed at the times shown end assayed for activation peptide release.
plotted as percent of substrate activated, progress curves of activation were still identical for the two substrates (data not shown). However, because the factor X concentration was twofold higher than the factor IX concentration, the activation rate for factor X was about twofold higher than the activation rate for factor IX (for example, in one experiment, 37.8 nmol/L/h for factor X and 19.0 nmol/L/h for factor IX).
Verification that factor VIIa/TF complexes catalyzed the activation of factors IX and X in the umbilical vein segment model. Because of the above observations, it was thought important to verify that the procoagulant activity provided by the umbilical vein was TF. First, anti-TF antibodies were shown to abolish the procoagulant activity of vein segments. An experimental vein segment was filled with buffer A containing anti-TF IgG, and a control vein segment from the same cord was filled with buffer A containing non-immune IgG. Both vein segments were incubated for 30 minutes at 37OC. Then, in the vein segment incubated with anti-TF IgG, the original buffer was replaced with buffer containing anti-TF IgG plus factor VIIa, calcium ions, and 'H-factor IX or 'H-factor X; in the vein segment incubated with nonimmune IgG, the original buffer was replaced with buffer containing non-immune IgG plus the other reactants. Progress curves of activation of the substrates were measured, as shown for 'H-factor IX in Fig 5. Similar results were obtained for activation of factor X (data not shown).
Except for the experiment described earlier in which two veins were washed with EDTA, veins were not exposed to a calcium-chelating agent capable of dissociating factor VIIa/ TF complexes. Therefore, if the vein wall possessed TF activity in vivo, factor VIIa/TF complexes capable of activating factors IX and X might be present in our umbilical vein Paired umbilical vein segments were filled with buffer B and either tritiated factor IX or factor X, 88 nmol/L. The reaction mixture of one segment of the pair also contained added factor Vlla, 10 nmol/L. The segments were incubated at 37'C, and subsamples were removed over time for measurement of activation peptide release. model, even when exogenous factor VIIa was not added to reaction mixtures. On several occasions, paired segments of a vein were filled with buffer A containing substrate and calcium ions, but exogenous factor VIIa was added to the reaction mixture of only one of the segments. Whereas factors IX and X were activated faster in reaction mixtures containing exogenous factor VIIa, both substrates were also activated in reaction mixtures containing no exogenous factor VIIa (Table 1) .
A final experiment was done in which vein segments were filled with buffer A containing either anti-factor VI1 IgG or non-immune IgG (control). After 30 minutes at 37OC, the original buffer in the experimental vein segment was replaced with buffer containing anti-factor VI1 IgG, calcium ions, and either 'H-factor IX or 'H-factor X. The original buffer in the control vein segment was replaced with buffer containing all reactants except anti-factor VI1 IgG. As shown in Fig 5, antibodies to factor VI1 abolished activation of factor IX. Similar results were obtained for the activation of factor X (data not shown). Thus, factor VIIa was shown to be an absolute requirement for umbilical vein segments to support activation of factors IX and X.
The failure of heparin to increase rates of activation of factors IX and X in umbilical vein segments. In our previous study, heparin was found to increase the rate of factor VIIa/TF-catalyzed activation of both factor IX and factor X in reaction mixtures made with purified TF reconstituted into phospholipid vesicles, and also when the factor VIIa/TF complexes were formed on the membrane of perturbed cultured HUVEC monolayers.' Thus, in six experiments with complexes formed on HUVEC, mean rates of activation were as follows: for factor X, 24.5 f 6.6 nmol/L/h without heparin and 38.5 15.4 nmol/L/h with heparin; for factor IX, 6.1 + 2.7 nmol/L/h without heparin and 13.1 5.2 nmol/L/h with heparin. In contrast, in six experiments in which heparin, 1 U/mL, was added to the reaction mixture of only one of two paired segments, heparin failed to accelerate the rate of activation of either factor X or factor IX. In three paired segments with factor X as substrate, mean activation rates were as follows: without heparin, On two occasions, segments of umbilical vein were cut in cross section for histologic examination of parafin sections stained with hematoxylin and eosin. Vein segments were examined under two conditions. In one, the veins were washed free of blood but not otherwise treated. In the other, veins were washed free of blood, filled with reaction mixture, and subjected to the alterations of intraluminal pressure resulting from periodic mixing of the reaction mixture by the twosyringe technique, as described in Methods. After just Histologic studies of the umbilical vein model.
washing the blood from the vein, much of its endothelium appeared intact, but some areas of the vein with denuded endothelium were also noted. After the vein had been subjected to the intraluminal pressures induced by periodic mixing of the reaction mixture, much of the endothelial lining of the vein wall was lost.
Umbilical veins processed as for the present experiments were also subjected to immunostaining for tissue factor antigen. Figure 6 is a microphotograph of a vein that had been washed free of blood but had not been subjected to the intraluminal pressures arising from repeated mixing of a reaction mixture. Endothelial cells can be seen lining most of the luminal surface of the vein and do not stain for tissue factor antigen. This was a consistent finding; patches of endothelium persisting after a vein had been subjected to repeated mixing of a reaction mixture also failed to stain. In contrast (Fig 6) , intense staining for tissue factor antigen was repeatedly observed within fenestrations of the muscularis media of the umbilical vein and in the mucoid connective tissue (Wharton's jelly) surrounding the vein.
DISCUSSION
In the umbilical vein model a washed segment of umbilical vein is filled with a reaction mixture containing factor VIIa, calcium ions, and a substrate, either 'H-factor IX or 'Hfactor X. Thevein wall provides the TF needed to form factor VIIa/TF complexes, which can then activate the substrates. Activation rates are calculated from measurements of 'Hactivation peptide release from serial subsamples of reaction mixtures. Before a subsample is removed, a reaction mixture is mixed thoroughly by a repeated back and forth flow of the reaction mixture into syringes inserted into each end of the vein segment.
The model was developed for an intended study of the functional properties of T F induced on venous endothelium in situ. TF activity on monolayers of cultured HUVEC is measurable only after monolayers are exposed to a perturbing stimulus, such as thrombin or a phorbol ester.'.' Therefore, it was surprising to discover that factors IX and X were activated in the umbilical vein model without first having to expose the vein wall to a known perturbing stimulus. Procoagulant activity similar to that found with routinely processed cords was also found in umbilical vein segments of cords processed by a modified technique, preventing blood clotting within the vein before it was washed free of blood (Fig 2) . Thus, thrombin formed intrinsically could not be implicated as a perturbing stimulus, bypassing the need for an exogenous perturbing stimulus.
Furthermore, procoagulant activity was present in umbilical vein segments of cords obtained from cesarean sections done before the onset of labor, which established that the activity did not reflect a response to stimuli arising during labor. Moreover, unlike cultured HUVEC, which express little or no surface membrane TF activity until several hours after exposure to various perturbing stimuli,'*2 the procoagulant activity of the umbilical vein model was independent of the elapsed time from delivery to processing of the cord (Fig  2) . Thus, all evidence suggested that the procoagulant activity was a constitutive property of the vein wall. This then raised two issues: first, was the procoagulant activity indeed TF, and, second, was the assumption valid that the procoagulant activity represented activity on endothelium?
Both antibodies against tissue factor and antibodies against factor VI1 (Fig 5) blocked activation of factors IX and X, which confirmed functionally that the activity was TF. Immunostaining experiments established that TF antigen was present within the vein wall. Thus, it was verified that the activations being measured in the model stemmed only from the catalytic activity of factor VIIa/TF complexes and that the T F required for the complexes was present within the vein wall.
However, histologic studies established that washing the blood from a vein and subsequently mixing a reaction mixture repeatedly within its lumen progressively disrupted the endothelial lining of the vein. Moreover, the endothelium failed to stain for TF antigen, whereas intense staining was noted within fenestrations of the underlying muscularis media and in the surrounding mucoid connective tissues of Wharton's jelly (Fig 6) . Consequently, a reaction mixture subjected to the intraluminal pressures arising from our mixing technique could readily come into contact with TF in the fenestrations of the muscularis media. The umbilical vein lacks a true adventitia, which allows extensions of Wharton's jelly to penetrate fenestrations within the muscular wall of the vein." Therefore, it would appear that our umbilical vein model provided data on the functional properties of factor VIIa/TF complexes formed not on venous endothelium but within the mucoid connective tissue of Wharton's jelly.
Factor VIIa/TF complexes made with TF in suspensionl.12-14 activate factor X substantially faster than they activate factor IX. Factor X also remains the preferred substrate when the membrane of cultured cells has provided the TF activity for factor VIIa/TF ~o m p l e x e s .~~'~* '~ Our results differ strikingly from the earlier observations in that factor VIIa/TF complexes activated factors IX and X at equivalent rates when reaction mixtures within umbilical vein segments contained equivalent substrate concentrations. If the concentration of factor X was increased to twice that of factor IX, ie, if substrates were present at their respective plasma concentrations, then the activation rate of factor X was approximately twice that of factor IX. This contrasts with the many-fold higher rate of activation of factor X than of factor IX at plasma concentrations of the substrates calculated from kinetic data obtained with T F in su~pension.'~.~' Adding heparin to reaction mixtures has been reported to favor factor VIIa/TF activation of factor IX." However, in our earlier experiments, adding heparin to reaction mixtures increased the factor VIIa/TF-catalyzed activation rates of both factor IX and factor X.' This was true whether the factor VIIa/TF complexes were formed with purified TF reconstituted into phospholipid vesicles or with T F expressed on the surface of perturbed, cultured HUVEC.' In contrast, in these experiments with the umbilical vein model, adding heparin to reaction mixtures failed to accelerate the activation rate of either factor IX or factor X. Since Wharton's jelly has long been known to be rich in tissue mast cells" and to stain metachromatically for sulfated proteoglycan, one may suspect that heparin or other glycosaminoglycans present in Wharton's jelly nullified the effect of exogenous heparin added to reaction mixtures. One may further suspect that the equivalent rates of factor VIIa/TF-catalyzed activation of factor IX and X also stem from an effect of glycosaminoglycans in the mucoid connective tissue of Wharton's jelly. Our data are insufficient to distinguish between an enhanced activation of factor IX or a diminished activation of factor X as an explanation for the equivalent rates of activation observed.
After factor VIIa/TF complexes were shown to activate factor IX,I9 physiologic significance of this finding was initially debated, because factor VIIa/TF complexes were repeatedly shown to activate factor X faster than they activated factor IX. However, substantial evidence has now accumulated-from experiments using tissue factor suspensions in purified" and plasma systems" and in experiments with TF on perturbed vascular endothelium2'-that establishes that factor VIIa/TF activation of factor IX significantly enhances the direct factor VIIa/TF activation of factor X when reaction mixtures contain a source of factor VIIIa. Therefore, it is increasingly appreciated that the factor VIIa/TF-catalyzed activation of factor IX represents a meaningful initial step in blood coagulation during h e m o~t a s i s .~~.~~ Our finding of equivalent rates of factor VIIa/TF activation of factors IX and X at equivalent substrate concentrations in the umbilical vein model strengthens the belief that factor VIIa/TF activation of factor IX represents a key initial reaction of coagulation in tissues in vivo. Our results also show the potential for error involved in extrapolating to coagulation in extravascular tissues kinetic data on factor VIIa/TF obtained with TF expressed on the surface membrane of cultured cells. Our findings with the umbilical vein model highlight the need to develop techniques to examine the function of factor VIIa/TF complexes formed within the extracellular matrix of other tissues.
